Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report) shares shot up 3.4% during trading on Wednesday . The stock traded as high as $0.7034 and last traded at $0.6933. 73,291 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.6705.
Emerald Bioscience Stock Performance
The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $0.80. The stock has a market capitalization of $185.86 million, a PE ratio of -8.67 and a beta of 0.43.
Emerald Bioscience Company Profile
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Read More
- Five stocks we like better than Emerald Bioscience
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
